课题基金 / 基金详情

B-Lymphocyte Immunotherapy in Islet Transplantation

B-Lymphocyte Immunotherapy in Islet Transplantation
胰岛移植中的 B 淋巴细胞免疫治疗
批准号:
8141988
负责人:
Ali Naji
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2012-07-31

项目摘要

项目成果

Ali Naji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Islet transplantation can restore endogenous insulin secretion in patients with type 1 diabetes (T1D) and consequently enable the attainment of near-normal glycemic control in the absence of severe episodes of hypoglycemia. At the University of Pennsylvania, we have been investigating the efficacy of combined B- and T- lymphocyte directed immunotherapy for promoting immunological tolerance to islet allografts in TID patients (CIT 05). We are also participating in the phase 3 FDA registration trial investigating a T-cell directed immunotherapy (CIT 07), and the islet-after-kidney (lAK) trial in T1D subjects following successful renal transplantation (CIT 06). Penn actively participated in the development of the Consortium Standard Operating Procedures using Serva collagenase in islet manufacturing. Penn became the first center to qualify to proceed with islet transplantations in 2008, and in that year performed three clinical transplants using single islet donors. The initiation of clinical islet transplantation provided the unique opportunity to utilize metabolic and immunologic mechanistic studies to gain insight into beta cell secretory capacity and immunological alterations in lymphocyte phenotype and function after islet transplantation, respectively. Having achieved these milestones of islet manufacturing and transplantation, we are committed to completing the Consortium clinical trials and the accompanying metabolic and immunologic studies. RELEVANCE: Type 1 diabetes (T1 D) results from the selective loss of insulin-producing beta cells in pancreatic islets. Despite a multitude of advanced insulin delivery systems, subjects with TID continue with abnormal fluctuations in glucose level, leading to the development of secondary complications of the disease. Islet transplantation has the potential to provide precise and long term control of glucose metabolism, thus preventing secondary complications of the disease.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.2337/dc16-2691
发表时间: 2017
期刊: Diabetes care
影响因子: 16.2
作者: [Hering,BernhardJ, Bridges,NancyD, Eggerman,ThomasL, Ricordi,Camillo, ClinicalIsletTransplantationConsortium]
通讯作者: ClinicalIsletTransplantationConsortium
DOI: 10.2337/db13-0867
发表时间: 2014-05
期刊: Diabetes
影响因子: 7.7
作者: [Metzger DE, Liu C, Ziaie AS, Naji A, Zaret KS]
通讯作者: Zaret KS
DOI: 10.1007/s11892-012-0294-3
发表时间: 2012-10
期刊: CURRENT DIABETES REPORTS
影响因子: 4.2
作者: [Rickels, Michael R.]
通讯作者: Rickels, Michael R.
Hypersensitivity to rabbit antithymocyte globulin in an islet transplant recipient: a case report.
胰岛移植受者对兔抗胸腺细胞球蛋白过敏:病例报告。
DOI: 10.1016/j.transproceed.2011.10.004
发表时间: 2011
期刊: Transplantation proceedings
影响因子: 0.9
作者: [Soleimanpour,SA, Sekiguchi,DR, LaRosa,DF, LuningPrak,ET, Naji,A, Rickels,MR]
通讯作者: Rickels,MR
Targeting Blys/Baff in non-human primate islet transplantation
  • 批准号:
    8519302
  • 项目类别:
  • 资助金额:
    $76.28万
  • 财政年份:
    2012
  • 负责人:
    Ali Naji
  • 依托单位:
Targeting Blys/Baff in non-human primate islet transplantation
  • 批准号:
    9113465
  • 项目类别:
  • 资助金额:
    $94.7万
  • 财政年份:
    2012
  • 负责人:
    Ali Naji
  • 依托单位:
Targeting Blys/Baff in non-human primate islet transplantation
  • 批准号:
    8400883
  • 项目类别:
  • 资助金额:
    $70.05万
  • 财政年份:
    2012
  • 负责人:
    Ali Naji
  • 依托单位:
Targeting Blys/Baff in non-human primate islet transplantation
  • 批准号:
    8706033
  • 项目类别:
  • 资助金额:
    $79.05万
  • 财政年份:
    2012
  • 负责人:
    Ali Naji
  • 依托单位:
海外基金